Menu
  • Join
  • Login
  • Contact
 

Search abstracts


IMPACT OF TACROLIMUS BLOOD CONCENTRATION ON CLINICAL OUTCOMES IN PATIENTS WITH MYASTHENIA GRAVIS

  • At: 2019 FIP Congress in AbuDhabi (United Arab Emirates)
  • Type: Poster
  • By: YAMAMOTO, Shota (Kyoto University Hospital, Department of Clinical Pharmacology and Therapeutics, Japan)
  • Co-author(s): Shota Yamamoto: Department of Clinical Pharmacology and Therapeutics, Kyoto University Hospital, Kyoto, Japan
    Atsushi Yonezawa: Department of Clinical Pharmacology and Therapeutics, Kyoto University Hospital, Kyoto, Japan
    Yuri Irachi: Department of Clinical Pharmacology and Therapeutics, Kyoto University Hospital, Kyoto, Japan
    Ikumi Hirozumi: Department of Clinical Pharmacology and Therapeutics, Kyoto University Hospital, Kyoto, Japan
    Yoshiki Katada: Department of Clinical Pharmacology and Therapeutics, Kyoto University Hospital, Kyoto, Japan
    Shunsaku Nakagawa: Department of Clinical Pharmacology and Therapeutics, Kyoto University Hospital, Kyoto, Japan
    Mitsuhiro Sugimoto: Department of Clinical Pharmacology and Therapeutics, Kyoto University Hospital, Kyoto, Japan
    Yuko Yoshida: Department of Clinical Pharmacology and Therapeutics, Kyoto University Hospital, Kyoto, Japan
    Tomohiro Omura: Department of Clinical Pharmacology and Therapeutics, Kyoto University Hospital, Kyoto, Japan
    Etsuro Nakanishi: Department of Neurology, Kyoto University Graduate School of Medicine, Kyoto, Japan
    Ryosuke Takahashi: Department of Neurology, Kyoto University Graduate School of Medicine, Kyoto, Japan
    Kazuo Matsubara: Department of Clinical Pharmacology and Therapeutics, Kyoto University Hospital, Kyoto, Japan
  • Abstract:

    Background

    Myasthenia gravis (MG) is an autoimmune disease caused by autoantibodies acting primarily against acetylcholine receptors (AChRs), and needs the high-dose and long-continued therapy with prednisolone (PSL) for its treatment. In the clinical practice guideline for MG, it has been described that introduction of tacrolimus (TAC) at early..

  • The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress. Please login
Last update 21 September 2019

FIP Congresses